Cardlytics (NASDAQ:CDLX - Get Free Report) will likely be releasing its Q2 2025 earnings data after the market closes on Wednesday, August 6th. Analysts expect Cardlytics to post earnings of ($0.16) per share and revenue of $64.06 million for the quarter.
Cardlytics Stock Down 7.8%
Shares of NASDAQ CDLX traded down $0.16 during midday trading on Friday, hitting $1.88. 889,076 shares of the stock traded hands, compared to its average volume of 1,903,461. The company has a market cap of $98.70 million, a PE ratio of -0.53 and a beta of 1.26. Cardlytics has a one year low of $1.22 and a one year high of $7.78. The business has a 50 day moving average price of $1.88 and a two-hundred day moving average price of $2.17. The company has a debt-to-equity ratio of 2.62, a quick ratio of 1.19 and a current ratio of 1.19.
Analysts Set New Price Targets
Separately, Lake Street Capital dropped their price target on Cardlytics from $3.00 to $2.50 and set a "hold" rating on the stock in a research report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Cardlytics has a consensus rating of "Hold" and a consensus target price of $3.50.
Read Our Latest Report on CDLX
About Cardlytics
(
Get Free Report)
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Further Reading

Before you consider Cardlytics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.
While Cardlytics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.